1. Biochemistry and Chemical Biology
  2. Structural Biology and Molecular Biophysics
Download icon

Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol

  1. Kelly A Manthei
  2. Shyh-Ming Yang
  3. Bolormaa Baljinnyam
  4. Louise Chang
  5. Alisa Glukhova
  6. Wenmin Yuan
  7. Lita A Freeman
  8. David J Maloney
  9. Anna Schwendeman
  10. Alan T Remaley
  11. Ajit Jadhav
  12. John JG Tesmer  Is a corresponding author
  1. University of Michigan, United States
  2. National Institutes of Health, United States
  3. National Heart, Lung, and Blood Institute, National Institutes of Health, United States
  4. Purdue University, United States
Research Article
  • Cited 13
  • Views 1,740
  • Annotations
Cite this article as: eLife 2018;7:e41604 doi: 10.7554/eLife.41604

Abstract

Lecithin:cholesterol acyltransferase (LCAT) and LCAT-activating compounds are being investigated as treatments for coronary heart disease (CHD) and familial LCAT deficiency (FLD). Herein we report the crystal structure of human LCAT in complex with a potent piperidinylpyrazolopyridine activator and an acyl intermediate-like inhibitor, revealing LCAT in an active conformation. Unlike other LCAT activators, the piperidinylpyrazolopyridine activator binds exclusively to the membrane-binding domain (MBD). Functional studies indicate that the compound does not modulate the affinity of LCAT for HDL, but instead stabilizes residues in the MBD and facilitates channeling of substrates into the active site. By demonstrating that these activators increase the activity of an FLD variant, we show that compounds targeting the MBD have therapeutic potential. Our data better define the substrate binding site of LCAT and pave the way for rational design of LCAT agonists and improved biotherapeutics for augmenting or restoring reverse cholesterol transport in CHD and FLD patients.

Article and author information

Author details

  1. Kelly A Manthei

    Life Sciences Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3874-8228
  2. Shyh-Ming Yang

    National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1928-136X
  3. Bolormaa Baljinnyam

    National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Louise Chang

    Life Sciences Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Alisa Glukhova

    Life Sciences Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Wenmin Yuan

    Department of Pharmaceutical Science, Biointerfaces Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Lita A Freeman

    Lipoprotein Metabolism Section, Cardiovascular-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. David J Maloney

    National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Anna Schwendeman

    Department of Pharmaceutical Science, Biointerfaces Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Alan T Remaley

    Lipoprotein Metabolism Section, Cardiovascular-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Ajit Jadhav

    National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7955-1451
  12. John JG Tesmer

    Department of Biological Sciences, Purdue University, West Lafayette, United States
    For correspondence
    jtesmer@purdue.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1125-3727

Funding

National Heart, Lung, and Blood Institute

  • Alan T Remaley

National Center for Advancing Translational Sciences (Division of Preclinical Innovation)

  • Ajit Jadhav

American Heart Association (15POST24870001)

  • Kelly A Manthei

National Institutes of Health (F32HL131288)

  • Kelly A Manthei

American Heart Association (16POST27760002)

  • Wenmin Yuan

National Institutes of Health (HL071818)

  • John JG Tesmer

National Institutes of Health (HL122416)

  • John JG Tesmer

American Heart Association (13SDG17230049)

  • Anna Schwendeman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Arun Radhakrishnan, University of Texas Southwestern Medical Center, United States

Publication history

  1. Received: September 1, 2018
  2. Accepted: November 6, 2018
  3. Accepted Manuscript published: November 27, 2018 (version 1)
  4. Version of Record published: December 3, 2018 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,740
    Page views
  • 263
    Downloads
  • 13
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Biochemistry and Chemical Biology
    2. Neuroscience
    Ricardo M Santos, Anton Sirota
    Research Article Updated

    Cholinergic fast time-scale modulation of cortical physiology is critical for cognition, but direct local measurement of neuromodulators in vivo is challenging. Choline oxidase (ChOx)-based electrochemical biosensors have been used to capture fast cholinergic signals in behaving animals. However, these transients might be biased by local field potential and O2-evoked enzymatic responses. Using a novel Tetrode-based Amperometric ChOx (TACO) sensor, we performed highly sensitive and selective simultaneous measurement of ChOx activity (COA) and O2. In vitro and in vivo experiments, supported by mathematical modeling, revealed that non-steady-state enzyme responses to O2 give rise to phasic COA dynamics. This mechanism accounts for most of COA transients in the hippocampus, including those following locomotion bouts and sharp-wave/ripples. Our results suggest that it is unfeasible to probe phasic cholinergic signals under most behavioral paradigms with current ChOx biosensors. This confound is generalizable to any oxidase-based biosensor, entailing rigorous controls and new biosensor designs.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Manoj K Rathinaswamy et al.
    Research Article

    Class I Phosphoinositide 3-kinases (PI3Ks) are master regulators of cellular functions, with the class IB PI3K catalytic subunit (p110g) playing key roles in immune signalling. p110g is a key factor in inflammatory diseases, and has been identified as a therapeutic target for cancers due to its immunomodulatory role. Using a combined biochemical/biophysical approach, we have revealed insight into regulation of kinase activity, specifically defining how immunodeficiency and oncogenic mutations of R1021 in the C-terminus can inactivate or activate enzyme activity. Screening of inhibitors using HDX-MS revealed that activation loop-binding inhibitors induce allosteric conformational changes that mimic those in the R1021C mutant. Structural analysis of advanced PI3K inhibitors in clinical development revealed novel binding pockets that can be exploited for further therapeutic development. Overall this work provides unique insights into regulatory mechanisms that control PI3Kg kinase activity, and shows a framework for the design of PI3K isoform and mutant selective inhibitors.